SignalCorporate

Cell and Gene Therapy Contract Research Organization Market Report 2026 | Capitalize on 12.3% CAGR as Thermo Fisher, IQVIA, Labcorp, ICON, and WuXi AppTec Scale Integrated Trials

12.3% CAGR and named CROs scaling integrated trials drive market report relevance.

Context

What happened: ResearchAndMarkets.com added a 2026 report on the cell and gene therapy contract research organization market, covering companies including Thermo Fisher, IQVIA, Labcorp, ICON, and WuXi AppTec. Key numbers: Market projected at $6.92 billion in 2025, $7.76 billion in 2026 (12.1% CAGR), and $12.36 billion by Why it matters: Growth is attributed to rising gene therapy trial activity, oncology and genetic disorder investment, personalized medicine programs, and demand for faster timelines, with outsourcing and integrated preclinical and clinical services cited as key trends. Market: +0.3% today ($675.90), +14.3% YTD, 0.3x vol — as of 16:49 UTC

What changed

ResearchAndMarkets.com added a 2026 report on the cell and gene therapy contract research organization market, covering companies including Thermo Fisher, IQVIA, Labcorp, ICON, and WuXi AppTec.

Why it matters

Growth is attributed to rising gene therapy trial activity, oncology and genetic disorder investment, personalized medicine programs, and demand for faster timelines, with outsourcing and integrated preclinical and clinical services cited as key trends. Market: +0.3% today ($675.90), +14.3% YTD, 0.3x vol — as of 16:49 UTC

Sources

eodhd